AEON Biopharma, Inc. (AEON) Stock

Healthcare · Biotechnology · Member of Other US Stocks

AEON Biopharma, Inc. (AEON) closed at USD 0.23 on 2026-10-14, a change of -75.4 % over the past year, with a market capitalization of USD 12.12M.

AEON Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AEON Biopharma, Inc. key figures

Previous close

USD 0.23 (2026-10-14)

1-year change

-75.4 %

Market cap

USD 12.12M

Enterprise value

USD 11.47M

P/E ratio (trailing)

-0.05

P/E ratio (forward)

-0.96

EPS (trailing)

-4.64

EPS (forward)

-0.25

PEG ratio

n/a

Price to book

-0.42

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.13

Employees

8

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AEON Biopharma, Inc. and compare it with other stocks.